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Objectives: 1. To determine BMI, obesity/overweight rates, glucose and lipids at baseline, during GnRHa treatment
and shortly after therapy discontinuation in female children with CPP and EP. 2. To compare this response to that
seen in a similar group of untreated patients.
Methods: A retrospective analysis of 71 children with either CPP (n = 37) or EP (n = 34) was undertaken. Forty three
were treated with a GnRHa for at least 2 years, while 28 were followed without treatment.
Results: At the time of diagnosis, a higher BMI (z-score of 1.1 ± 0.8 vs. 0.6 ± 0.7, p = 0.004) and a higher prevalence of
obesity/overweight (72.9 vs. 35.3%, p = 0.001) was observed in subjects with CPP when compared to those with EP.
Children with EP had higher fasting glucose and total cholesterol than those with CPP. BMI z-score, obesity/overweight
rates, fasting glucose and lipids did not change significantly in girls with CPP or EP during 3 yrs of follow up, regardless
of treatment. Weight z-scores were higher at 3 years in treated than in untreated girls with CPP (p = 0.02), while it was
higher in untreated than in GnRHa-treated patients with EP at baseline, 1, 2 and 3 years (p = 0.007, p = 0.002, p = 0.02
and p = 0.04, respectively) and remained so shortly after stopping therapy (p = 0.03).
Conclusions: There is a high prevalence of obesity/overweight in girls with CPP and EP at diagnosis. However, this risk
is greater in CPP than in EP girls. BMI, Obesity/overweight rates, fasting glucose and lipids remained stable in CPP and
EP girls regardless of therapy. Weight z-scores were found to be higher in treated CPP girls and in untreated girls
with EP.
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Central precocious puberty (CPP) and early puberty (EP)
may be associated with an increased body mass index
(BMI), adiposity, and with an increased prevalence of
obesity before, during and after discontinuing GnRH ana-
log (GnRHa) treatment when compared with age- and
sex-matched reference values of the same population
[1-4]. Until 2012, around 20 studies had addressed the* Correspondence: acolmena62@hotmail.com
1Department of Pediatrics, Hospital Dr. Patrocinio Peñuela-IVSS, San Cristobal,
Táchira 5001, Venezuela
Full list of author information is available at the end of the article
© 2014 Colmenares et al.; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.BMI outcome and the prevalence of obesity in children
with CPP or EP treated with a GnRHa [1-3,5-17]. Of these
only two studies analyzed patients with EP separately
[18,19]. Additionally only two previous publications
reported on the evolution of glucose and lipids during
GnRHa therapy [4,20]. The consensus statement on the
use of GnRHa in children [21] highlighted the need for
studies regarding body composition, fat distribution or
metabolic syndrome in this population.
Data in the literature concerning the influence of
GnRHa therapy on the evolution of BMI and the rate of
obesity-overweight in children with CPP and EP remainntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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CPP seems to be unrelated to GnRHa administration
[1,6] and girls treated in childhood with a GnRHa have
been found to have a normal BMI and body composition
in early adulthood [17]. However in other reports a posi-
tive correlation between BMI before GnRHa administra-
tion and BMI after this treatment has been shown [7,22]
and an increase in BMI, total body fat, and in insulin
resistance has been described in some GnRHa-treated
CPP subjects [4,15,23]. Only one publication docu-
mented a reduction of BMI z-score and of the obesity
rate in girls with CPP during GnRHa treatment [11].
In this unicenter study we assessed BMI, rate of obesity
and overweight, as well as fasting glucose and lipid profiles
at the time of diagnosis, during at least 2 years of GnRHa
therapy and shortly after treatment discontinuation in a
group of 71 girls affected by CPP or by EP. We compared
results at these time periods between CPP and EP patients
with a similar group of untreated patients.
Subjects and methods
The medical records of 130 girls with a diagnosis of early
or precocious puberty from the Pediatric Endocrine Unit
of the Hospital de Clínicas Caracas were screened. Of
these we selected only those records (n = 71) that met the
following inclusion criteria: 1. Confirmed CPP or EP: a)
onset of breast development (stage B2 or above according
to Tanner) before a chronological age of 9 yrs, b) pubertal
LH response (>7 IU/liter) to a GnRH stimulation test, c)
advancement of bone age over chronological age by at
least 1 yr, d) pubertal uterine and ovarian volume at pelvic
ultrasonography [24]. 2. No evidence of hypothalamic-
pituitary organic lesions following magnetic resonance
imaging. 3. Absence of other conditions that might
affect the onset of puberty and the BMI (e.g. GH defi-
ciency, congenital adrenal hyperplasia, hypothyroidism).
4. Regular follow up during at least 2 years. 5. Measure-
ment of lipid and glucose levels once a year during at least
2 years of follow up. 6. Compliance with the GnRHa
treatment during the period of follow up. 7. Confirmed
gonadotropin suppression throughout the period of GnRHa
administration.
According to criteria previously established, we excluded
all patients with isolated thelarche, non progressive forms
of puberty, normal puberty, non confirmed laboratory
tests suggestive of advanced puberty at diagnosis, incom-
plete medical records, irregular follow up, absence of lipid
and glucose measurements at baseline or at follow, less
than 2 years of follow up and no treatment compliance.
Patients were diagnosed with CPP (n = 37) if clinically
and biochemically confirmed puberty presented at less
than 8 yrs of age and they were diagnosed with EP (n = 34)
if puberty was confirmed between the ages of 8–9 yrs.
Based on the therapeutic policy of our Pediatric EndocrineUnit at that time, gonadotropin-suppressive therapy was
offered to all the girls after an observation period of 1 to
3 months in order to rule out transient or slowly progres-
sive forms of puberty, which do not require treatment.
Therapy was offered on the basis of either: 1. A diagnosis
of a rapidly progressive form of CPP, regardless of stature,
2. A rapidly progressive form of EP associated with emo-
tional difficulties or a low predict adult height. Of the CPP
girls, 29 accepted treatment, 5 had a slowly progressive
form of CPP and were therefore not treated and 3 refused
therapy. Of the EP girls, 20 were followed without therapy,
while 14 were treated. Those who had a slowly progressive
form of CPP and EP or refused therapy were included in
the study as controls.
GnRHa treatment consisted of depot-triptorelin,
3.75 mg im every 28 days. During treatment, gonadotropin
suppression was regularly confirmed clinically and by pre-
pubertal levels of LH following acute iv LHRH stimulation
(LH <2 mIU/ml). Therapy was discontinued at a bone age
of 11.5 to 12.5 yrs. The duration of GnRHa-therapy was
2–4 yrs.
Patients with an elevated BMI at every evaluation were
recommended to increase physical activity and to improve
nutritional habits (to eat more fruits, grains and vegetables
and to decrease their caloric intake). The number of
patients in each group that were recommended to diet
and to increase physical activity was not significantly
different (CPP: 79.3 vs. 50%, p = 0.17 and EP: 29 vs. 40%,
p = 0.71, for treated vs. untreated patients respectively).
Methods
A retrospective analysis of the medical records of these
patients was undertaken. All patients had been evaluated
every 3–4 months by the same pediatric endocrinologist.
Body weight was measured with an electronic scale to the
nearest 0.1 kg. Height was measured with a Harpender
stadiometer to the nearest millimeter. BMI was calculated
as weight (kilograms)/height (meter square) and was
expressed as Z-score (z-scores) for chronological age
according to the CDC reference range [25]. Using
Venezuelan BMI percentile cut-off values, we defined
overweight as above the 90th percentile and obesity as
above the 97th percentile [26]. Centile curves were
drawn so that at age 18 years they passed through the
widely used cut off points of 25 and 30 kg/m(2) for
adult overweight and obesity.
Laboratory evaluation included measurement of LH,
FSH, estradiol, fasting glucose and lipid levels (total chol-
esterol, high density lipoprotein cholesterol (HDL-C), and
triglycerides). According to hospital policy blood samples
were obtained early in the morning in the fasting state in
all patients and with the proper parental approval. Serum
LH, FSH, and estradiol levels were measured by chemolu-
minescence in an Immulite autoanalyzer using reagents
Table 1 Baseline characteristics of patients with CPP
and EP
CPP EP p value
n 37 34 -
Treated/Untreated 29/8 14/20 -
Clinical characteristics -
Chronological age (yr) 7.4 ± 1.3 8.8 ± 0.6 0.001
Bone age (yr) 8.7 ± 2.1 9.3 ± 1.3 NS
Weight (Kg) 32.1 ± 6.7 32.6 ± 4.4 NS
Weight (z-score) 1.4 ± 0.8 1.9 ± 1.2 0.001
Height (SDS) 2.8 ± 1.2 1.3 ± 1.1 0.001
BMI (Kg/m2) 18.8 ± 2.4 18.2 ± 2 NS
BMI (z-score) 1.1 ± 0.8 0.6 ± 0.7 0.004
Obesity/Overweight n(%) 27 (72.9) 12 (35.3) 0.001
Obesity n(%) 9 (24.3) 3 (8.8) NS
Overweight n(%) 18 (48.6) 9 (26.5) 0.054
Predict adult height (SDS)
(SDS) (SDS)
0.3 ± 2.3 1.5 ± 1.2 0.04
Height velocity (SDS) 1.6 ± 2.1 1.8 ± 1.8 NS
Hormonal evaluation
DHEAS (ng/ml) 51.1 ± 34.2 52.8 ± 23.7 NS
LH peak (IU/L) 10.9 ± 7.3 6.1 ± 4.5 0.01
LH to FSH stimulated ratio 1.1 ± 0.7 1.1 ± 1.7 NS
Estradiol (pg/ml) 22.3 ± 17 14 ± 11.8 0.01
Ovarian volume (ml) 1.7 ± 0.7 1.8 ± 0.5 NS
Uterine length (cm) 3.7 ± 1.2 3.4 ± 1 NS
Metabolic profile
Fasting glucose (mg/dl) 73.3 ± 8.5 80.2 ± 10.2 0.04
Total Cholesterol (mg/dl) 158.6 ± 31.9 185.6 ± 35.7 0.02
LDL-C (mg/dl) 97 ± 35.1 113.2 ± 17.6 NS
HDL-C (mg/dl) 45 ± 8.9 53 ± 9.1 NS
TGR (mg/dl) 89.8 ± 46.7 104.8 ± 48.8 NS
TGR/HDL-C ratio 2.2 ± 0.9 1.5 ± 0.5 NS
Data are displayed as mean (± SDS). BMI, body mass index; DHEAS,
dehydroepiandrosterone sulfate; LH, luteinizing hormone; FSH, follicle-stimulating
hormone; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density
lipoprotein cholesterol; TGR, Triglycerides.
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USA). The intra- and interassay coefficients of variation
(CVs) were 5.7-6.1% and 5.3-6.5% for LH and FSH and
6.3%-6.4% for estradiol, respectively. Serum glucose,
total cholesterol, HDL-C and triglycerides where mea-
sured by enzymatic methods with a Technicon autoana-
lyzer (Boehringer Mannheim Diagnostics). LDL-C was
estimated using the Friedewald formula (LDL-C = TC –
Tg/5 + HDL-C) [27]. The triglyceride/HDL-C ratio was
calculated [28]. All assays were performed in the clinical
biochemistry laboratory of the Hospital. Total choles-
terol and triglyceride levels were compared to equiva-
lent Venezuelan reference data [26].
The data shown at baseline corresponds to the start of
treatment in GnRHa treated patients and the time of
confirmed diagnosis in non-treated patients. This means
that all patients had the same short period of follow up
between the first visit and the inclusion into the study.
We did not observe any significant difference in the
BMI of our patients during this short period of observa-
tion. In the analysis we also include the clinical data
from 9 patients shortly after discontinuation of GnRHa
therapy (6–12 months; mean of 9 ± 3 months). These
patients had previously received GnRHa treatment for at
least 2 years and therefore, all of them were included in
the 2 year analysis of the GnRHa treated group.
The institutional review board of the hospital ap-
proved the study, and informed consent for inclusion
into the study was obtained from all adolescents and
their parents.
Statistical analysis
All values are expressed as mean ± SDS unless other-
wise stated. Differences in categorical variables between
the groups were tested by the paired Fisher’s exact test.
Differences in the continuous variables comprised a
non parametric paired Wilcoxon signed rank test to
assess the changes between baseline values and all
other time points within the groups (intragroup com-
parison). Differences between GnRHa treated and non
treated patients (intergroup comparison) were assessed
by the non-paired non parametric Mann–Whitney sign
rank tests. Statistical significance was set at 5%. All statis-
tical analyses were performed by the SPSS computer
program, version 17.0 software for Windows (SPSS Inc.,
Chicago, IL, USA).
Results
Baseline characteristics of CPP and EP girls are summa-
rized in Table 1. All patients were in Tanner stage 2–3
of puberty. The CPP girls were younger (p = <0.001), had
a higher BMI (1.1 ± 0.8 vs. 0.6 ± 0.7 yr, p = 0.004) and a
higher prevalence of obesity and overweight (72.9 vs.
35.3%, p = 0.001) than the EP patients. Fasting glucoseand lipids were in the normal range for age and sex ac-
cording to Venezuelan reference values in all girls [26].
Mean total cholesterol levels at baseline, were however,
185.6 ± 35.7 mg/dl (in the 90th percentile) in EP patients.
The EP girls had higher fasting glucose (80.2 ± 10.2 vs.
73.3 ± 8.5 mg/dl, p = 0.04) and total cholesterol levels
(185.6 ± 35.7 vs. 158.6 ± 31.9 mg/dl, p = 0.02) than CPP
girls.
Tables 2 and 3 describe clinical and laboratory charac-
teristics of GnRHa treated and untreated females with
CPP and EP, respectively, during 3 years of follow up.
Table 2 Three years evolution in GnRHa treated and untreated patients with CPP
Baseline 1 yr 2 yrs 3 yrs
Treated Untreated Treated Untreated Treated Untreated Treated Untreated After Tx
CA (yr) 7.3 ± 1.5 7.7 ± 0.7 8.3 ± 1.5 8.7 ± 0.9 9.2 ± 1.5 9.6 ± 0.7 10.1 ± 1.5 10.7 ± 1.2 11.04 ± 0.4
Weight (z-score) 1.4 ± 0.7 1.2 ± 0.8 1.4 ± 0.6 1.3 ± 0.8 1.3 ± 0.9 1.2 ± 0.7 1.6 ± 0.6* 0.9 ± 0.5 0.8 ± 0.9
BMI (z-score) 1.2 ± 0.9 1 ± 0.8 1.2 ± 0.7 1.1 ± 0.8 1.1 ± 1 1 ± 0.7 1.3 ± 0.8 0.7 ± 0.5 0.7 ± 0.9
Ob/over (%) 79.3 50 65.4 50 65.4 50 81.8 40 40
Obesity (%) 24.1 25 26.9 25 23.1 25 45.5 0 20
Overweight (%) 55.2 25 38.5 25 42.3 25 36.4 40 20
Glycemia (mg/dl) 73.1 ± 9.1 74 ± 7.6 79.6 ± 8.9 88.6 ± 6.5 76 ± 10.1 84.3 ± 11.7 84.4 ± 5.3 80 ± 2.6 81 ± 18.4
Total-C (mg/dl) 156 ± 31.5 167.6 ± 35.7 172.1 ± 34.8 146.5 ± 42.3 152.8 ± 38.6 177.3 ± 23.9 159.2 ± 26.5 171.7 ± 39.1 167.3 ± 19.4
LDL-C (mg/dl) 96.6 ± 38.1 99.5 ± 16.3 108.1 ± 19.1 71.3 ± 24.1 92.9 ± 30.5 112.5 ± 7.8 100.2 ± 22.8 128.8 ± 13.9 122.5 ± 2.1
HDL-C (mg/dl) 43.8 ± 9 52 ± 7.1 35 ± 10.1 37.3 ± 9 48.5 ± 12.8 37 ± 4.2 43.8 ± 14 45.5 ± 2.1 44.5 ± 14.9
TRG (mg/dl) 83.3 ± 36.2 115.8 ± 78.5 80.9 ± 30.7 90.8 ± 33.7 79.9 ± 46.5 117 ± 66.8 83.3 ± 52.7 98.5 ± 37.5 64 ± 31.1
TRG/HDL-C ratio 2.1 ± 0.8 3 ± 1.5 2.5 ± 1 2.4 ± 0.5 1.7 ± 1.2 2.9 ± 2.2 1.9 ± 1.3 2.2 ± 0.9 2 ± 0.8
Data are expressed as mean ± SDS. SDS denotes the standard-deviation score for age and sex.
After Tx, after treatment; CA, Chronological age; BMI, body mass index; Ob/Over, obesity and overweight rate; Total-C, total cholesterol; LDL-C, Low density
lipoprotein cholesterol; HDL-C, High density lipoprotein cholesterol; TGR, Triglycerides.
*p 0.02, treated vs. untreated at 3 years of follow up.
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Weight and BMI z-scores remained unchanged over
the first 2 years in both GnRHa-treated and un-
treated subjects. However, at 3 years of follow up,
weight z-scores were higher in GnRHa-treated than
in untreated patients (p = 0.02) and BMI z-scores
followed this same trend, but did not reach signifi-
cance (p = 0.06). A decreasing trend in weight and
BMI z-scores was also detected in GnRHa-treatedTable 3 Three years evolution of GnRHa treated and untreate
Baseline 1 yr
Treated Untreated Treated Untreate
CA (yr) 8.9 ± 0.6 8.8 ± 0.5 9.9 ± 0.6 9.8 ± 0.6
Weight (z-score) 0.3 ± 0.7* 0.9 ± 0.6 0.1 ± 08* 0.9 ± 0.3
BMI (z-score) 0.4 ± 0.7 0.9 ± 0.6 0.3 ± 0.8 0.8 ± 0.5
Ob/over (%) 29 40 14 15
Obesity (%) 0 15 0 5
Overweight (%) 29 25 14 10
Glycemia (mg/dl) 79 ± 9.9 81.3 ± 11.1 89 ± 15.3 83.3 ± 9.7
Total-C (mg/dl) 195 ± 36.4 178.3 ± 35.5 184.8 ± 37.1 183.5 ± 33
LDL-C (mg/dl) 125 ± 38.4 113.2 ± 17.6 117.5 ± 42.8 131.5 ± 28
HDL-C (mg/dl) 50.6 ± 1.8 53 ± 9.1 51.3 ± 4.8 42.1 ± 7.4
TGR (mg/dl) 92.5 ± 30.9 113.4 ± 58.3 110 ± 43 73.9 ± 18
TGR/HDL-C ratio 1.8 ± 0.6 1.5 ± 0.5 2.2 ± 1.3 1.9 ± 0.5
Data are expressed as mean ± SDS. SDS denotes the standard-deviation score for ag
After Tx, after treatment; CA, Chronological age; BMI, body mass index; Ob/Over, ob
lipoprotein cholesterol; HDL-C, High density lipoprotein cholesterol; TGR, Triglycerid
*p <0.05 treated vs. untreated patients.
**p 0.03 untreated vs. patients after stop treatment.patients shortly after stopping therapy, but did not
reach significance (n = 37, see Table 2).
At the time of diagnosis, both GnRHa-treated and un-
treated patients had a high prevalence of obesity and
overweight. During 3 years of follow up, the prevalence
of obesity and overweight remained unchanged in both
groups of patients. In GnRHa treated patients who
stopped treatment following at least 2 years of therapy,
the rate of obesity and overweight showed a decreasing,d patients with EP
2 yrs 3 yrs
d Treated Untreated Treated Untreated After Tx
10.8 ± 0.7 10.7 ± 0.6 11.6 ± 0.7 11.5 ± 0.5 11.8 ± 0.4
0.2 ± 0.9* 0.9 ± 0.4 0.1 ± 0.9* 0.9 ± 0.5** −0.1 ± 1.1
0.4 ± 0.9 0.7 ± 0.6 0.3 ± 1.2 0.8 ± 0.6 0 ± 0.8
33 32 28.6 27 0
0 0 0 9 0
33 32 28.6 18 0
84.3 ± 6.1 81.2 ± 8.6 84 ± 5.7 83 ± 6.4 83
.8 186.8 ± 25 187.7 ± 41.8 133.5 ± 0.7 139.4 ± 37.6 123
.4 89.6 ± 66 105.8 ± 21.8 70.8 ± 5.1 83.7 ± 6.5 N.A
47.7 ± 2.5 56 ± 24.3 49 ± 1.4 34.3 ± 4 N.A
88 ± 18.5 85 ± 36 68.5 ± 14.9 96.5 ± 36.6 N.A.
1.8 ± 0.3 1.5 ± 1 1.4 ± 0.3 2 ± 0.5 N.A.
e and sex.
esity and overweight rate; Total-C, total cholesterol; LDL-C, Low density
es.
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3 years of follow up the prevalence of obesity and over-
weight were similar between groups, but tended to be
lower in untreated patients and in treated girls shortly
after GnRHa discontinuation. Fasting glucose, total
cholesterol, LDL, HDL-cholesterol, triglycerides and the
triglyceride/HDL-cholesterol ratio, remained unchanged
over the 3-year period, regardless of whether patients were
treated or not. We found no differences between treated
and untreated children for fasting glucose and lipids at
baseline and during 3 years of follow up.
Early Puberty patients (EP)
Weight and BMI z-scores remained unchanged over
3 years in both GnRHa-treated and untreated subjects.
However, during the 3 year follow up period, weight z-
scores were higher in untreated than in GnRHa-treated
patients (p = 0.007, p = 0.002, p = 0.02, p = 0.04 at base-
line, 1, 2 and 3 years, respectively); a similar trend was
observed in BMI z-scores, but the differences were not
significant. Weight z-scores were also significantly higher
in untreated subjects than in treated subjects shortly
after stopping therapy (p = 0.03) (n = 34, see Table 3).
Prevalence of obesity-overweight remained unchanged
over 3 years of follow up regardless of whether patients
were treated or not. A decreasing tendency was, however,
noted in GnRHa-treated girls shortly after therapy dis-
continuation. Fasting glucose, total cholesterol, LDL,
HDL-cholesterol, triglycerides and the triglyceride/
HDL-cholesterol ratio, remained unchanged over the
3-year period, regardless of whether patients were treated
or not. We found no differences between treated and
untreated children for fasting glucose and lipids at baseline
and during 3 years of follow up.
Discussion
Our study confirms the high prevalence of obesity and
overweight in girls with CPP and EP at the time of diag-
nosis. However, CPP girls presented with a higher BMI
z-score and a higher prevalence of obesity and over-
weight than EP patients at baseline. The reason why so
many subjects with CPP and EP have a BMI SDS above
the 90th percentile for chronological age is unclear.
Whether the hormonal changes of puberty trigger an in-
crease in BMI or whether a preexisting increased in BMI
contributes to the onset of puberty at an earlier age is
still not clear [29,30].
However, our study showed no difference in the BMI
z-score and the obesity/overweight rates over the 3-year
period of follow up, regardless of whether patients with
CPP or EP were treated or not. This finding is confirmed
by previous studies [1,14] that reported no significant
change in BMI or obesity/overweight prevalence after
GnRHa therapy in subjects with CPP or EP.An interesting finding emerging at 3 years of follow
from our study is the higher weight z-score noted in
GnRHa treated than in untreated girls with CPP, with a
similar trend being observed for the BMI z-score. This
finding would suggest a negative influence of GnRHa
treatment on body weight after 3 years of follow up in
CPP girls. Furthermore, both our patients with CPP or
EP showed a decreasing trend in BMI z-scores and in the
obesity/overweight rate following GnRHa treatment dis-
continuation. Accordingly, some previous studies have
demonstrated that the mean BMI z-score returned to
pre-treatment values after therapy withdrawal [2,9,19].
The administration of GnRHa to girls with EP has
been associated with greater BMI z-score at the end of
therapy [19]. However in our cohort of EP patients, it is
of interest to note that non-treated girls had a signifi-
cantly higher weight z-scores than treated patients at
baseline and that this difference remained unchanged
over the three year follow-up, despite GnRHa treatment.
Sorensen et al. [20] observed higher fasting insulin, tri-
glycerides, and LDL-cholesterol levels compared with
controls in 23 girls with CPP and EP at the time of diag-
nosis. In our cohort of girls with CPP and EP, glucose,
triglycerides, LDL- and HDL-cholesterol and the trigly-
ceride/HDL-C ratio were in the normal range at the
time of diagnosis and remained unchanged at 1, 2 and
3 years of follow up, regardless of whether they were
treated or not. An unexpected finding are the higher
fasting glucose and total cholesterol levels noted in EP
than in CPP patients at the time of diagnosis, despite the
higher BMI and obesity/overweight prevalence in the
latter group. Even though we cannot explain this finding,
it lead us to suggest that the higher prevalence of obes-
ity/overweight in CPP patients could be an artifact due
to the shift of the SD curve in puberty that is now
applied on younger children.
A limitation of this study is the small sample of girls
with CPP or EP, especially after therapy withdrawal, which
could limit the statistical power of the analysis. As to
insulin measurements, the blood sample we had was
small and did not allow us to measure this parameter in
our analysis. Data regarding the parental weight is lacking
in different studies, including ours, and increased weight
in parents certainly increases the risk of being overweight
in childhood [31].
In summary, there is a high prevalence of obesity and
overweight among girls with CPP and EP at diagnosis.
This risk is greater in CPP than in EP girls. BMI z-scores
and obesity/overweight rates remain stable during GnRHa
therapy in girls with CPP and EP, but tend to decrease in
GnRHa treated patients once therapy is discontinued for
several months. Weight z-scores were higher at 3 years in
GnRHa treated than in untreated girls with CPP, while
they were higher in untreated subjects with EP during the
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lipids, however, were in the normal reference ranges at the
time of diagnosis and remained stable during the 3 year
period of follow up, regardless of whether patients were
treated or not, so that the metabolic profile of CPP and EP
patients does not seem to be adversely affected by GnRHa
therapy.
Therefore, physicians treating patients with CPP and
EP must be aware of the increased BMI and obesity-
overweight prevalence rates seen at the moment of
diagnosis in these children and consider that these
parameters could persist or even increase further dur-
ing GnRHa treatment.
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